Re: CORT never disappoints
Returning cash to investor isn't the ideal as it's highly taxed. I'd prefer a share buyback (again lol) or that they invest massively in their business to make it grow faster... I don't hear much timing slippage when it comes to other biotechs but CORT seems to hold the pole position there. They absolutely need to deliver now. We are fortunate that they did an excellent job at keeping TEVA away for so long otherwise the company would have been in a very precarious position.
Also I'm still not over the AIWG failure.
Long term I think Relacorilant will be a success but we will have to wait another year. In the meantime and with the current macro condition I wouldn't rush into buying too much (I'm still holding a fraction of my shares).
We all know Q1 is the worst performing quarter (because of the reasons we all know) so we might have some weak stock price ahead.